Alessandra Fragale
Rome, 00161, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 19 publications
NSD2 and miRNAs as Key Regulators of Melanoma Response to Romidepsin and Interferon-α2b Treatment.
Journal: Cancer medicine
Published: September 18, 2024
RAF1 gene fusions are recurrent driver events in infantile fibrosarcoma-like mesenchymal tumors.
Journal: The Journal of pathology
Published: November 08, 2023
Targeting CXCR4 impaired T regulatory function through PTEN in renal cancer patients.
Journal: British journal of cancer
Published: September 20, 2023
CD8+CD103+PD1+TIM3+ T cells in glioblastoma microenvironment correlate with prognosis.
Journal: Immunology
Published: July 27, 2023
Reversing vemurafenib-resistance in primary melanoma cells by combined romidepsin and type I IFN treatment through blocking of tumorigenic signals and induction of immunogenic effects.
Journal: International journal of cancer
Published: December 22, 2022
Type I IFN-dependent antibody response at the basis of sex dimorphism in the outcome of COVID-19.
Journal: Cytokine & growth factor reviews
Published: September 24, 2020
Towards a Systems Immunology Approach to Unravel Responses to Cancer Immunotherapy.
Journal: Frontiers in immunology
Published: July 13, 2020
The Natural Agonist of Estrogen Receptor β Silibinin Plays an Immunosuppressive Role Representing a Potential Therapeutic Tool in Rheumatoid Arthritis.
Journal: Frontiers in immunology
Published: March 29, 2018
CSA and CSB play a role in the response to DNA breaks.
Journal: Oncotarget
Published: September 07, 2017
Targeting CXCR4 reverts the suppressive activity of T-regulatory cells in renal cancer.
Journal: Oncotarget
Published: May 07, 2017
Role of interferon regulatory factor 1 in governing Treg depletion, Th1 polarization, inflammasome activation and antitumor efficacy of cyclophosphamide.
Journal: International journal of cancer
Published: March 29, 2017
Last Updated: 09/26/2026